Serveur d'exploration MERS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?

Identifieur interne : 001935 ( PubMed/Checkpoint ); précédent : 001934; suivant : 001936

Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?

Auteurs : Emmanuel Faure [France] ; Julien Poissy [France] ; Anne Goffard [France] ; Clement Fournier [France] ; Eric Kipnis [France] ; Marie Titecat [France] ; Perinne Bortolotti [France] ; Laura Martinez [France] ; Sylvain Dubucquoi [France] ; Rodrigue Dessein [France] ; Philippe Gosset [France] ; Daniel Mathieu [France] ; Benoit Guery [France]

Source :

RBID : pubmed:24551142

Descripteurs français

English descriptors

Abstract

One year after the occurrence of the first case of infection by the Middle East Respiratory Syndrome coronavirus (MERS-CoV) there is no clear consensus on the best treatment to propose. The World Health Organization, as well as several other national agencies, are still working on different clinical approaches to implement the most relevant treatment in MERS-CoV infection. We compared innate and adaptive immune responses of two patients infected with MERS-CoV to understand the underlying mechanisms involved in the response and propose potential therapeutic approaches. Broncho-alveolar lavage (BAL) of the first week and sera of the first month from the two patients were used in this study. Quantitative polymerase chain reaction (qRTPCR) was performed after extraction of RNA from BAL cells of MERS-CoV infected patients and control patients. BAL supernatants and sera were used to assess cytokines and chemokines secretion by enzyme-linked immunosorbent assay. The first patient died rapidly after 3 weeks in the intensive care unit, the second patient still recovers from infection. The patient with a poor outcome (patient 1), compared to patient 2, did not promote type-1 Interferon (IFN), and particularly IFNα, in response to double stranded RNA (dsRNA) from MERS-CoV. The absence of IFNα, known to promote antigen presentation in response to viruses, impairs the development of a robust antiviral adaptive Th-1 immune response. This response is mediated by IL-12 and IFNγ that decreases viral clearance; levels of both of these mediators were decreased in patient 1. Finally, we confirm previous in vitro findings that MERS-CoV can drive IL-17 production in humans. Host recognition of viral dsRNA determines outcome in the early stage of MERS-CoV infection. We highlight the critical role of IFNα in this initial stage to orchestrate a robust immune response and bring substantial arguments for the indication of early IFNα treatment during MERS-CoV infection.

DOI: 10.1371/journal.pone.0088716
PubMed: 24551142


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:24551142

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?</title>
<author>
<name sortKey="Faure, Emmanuel" sort="Faure, Emmanuel" uniqKey="Faure E" first="Emmanuel" last="Faure">Emmanuel Faure</name>
<affiliation wicri:level="3">
<nlm:affiliation>Host-Pathogen translational research group, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Host-Pathogen translational research group, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Poissy, Julien" sort="Poissy, Julien" uniqKey="Poissy J" first="Julien" last="Poissy">Julien Poissy</name>
<affiliation wicri:level="3">
<nlm:affiliation>Pôle de Réanimation, Hôpital Roger Salengro, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Pôle de Réanimation, Hôpital Roger Salengro, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Goffard, Anne" sort="Goffard, Anne" uniqKey="Goffard A" first="Anne" last="Goffard">Anne Goffard</name>
<affiliation wicri:level="3">
<nlm:affiliation>Laboratoire de Virologie, Centre de Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Virologie, Centre de Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Fournier, Clement" sort="Fournier, Clement" uniqKey="Fournier C" first="Clement" last="Fournier">Clement Fournier</name>
<affiliation wicri:level="3">
<nlm:affiliation>Clinique des Maladies Respiratoires, Endoscopie bronchique et pleurale - Endoscopie Interventionnelle, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinique des Maladies Respiratoires, Endoscopie bronchique et pleurale - Endoscopie Interventionnelle, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kipnis, Eric" sort="Kipnis, Eric" uniqKey="Kipnis E" first="Eric" last="Kipnis">Eric Kipnis</name>
<affiliation wicri:level="3">
<nlm:affiliation>Host-Pathogen translational research group, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Host-Pathogen translational research group, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Titecat, Marie" sort="Titecat, Marie" uniqKey="Titecat M" first="Marie" last="Titecat">Marie Titecat</name>
<affiliation wicri:level="3">
<nlm:affiliation>Institut de Microbiologie, Centre Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Microbiologie, Centre Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Bortolotti, Perinne" sort="Bortolotti, Perinne" uniqKey="Bortolotti P" first="Perinne" last="Bortolotti">Perinne Bortolotti</name>
<affiliation wicri:level="3">
<nlm:affiliation>Host-Pathogen translational research group, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Host-Pathogen translational research group, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Martinez, Laura" sort="Martinez, Laura" uniqKey="Martinez L" first="Laura" last="Martinez">Laura Martinez</name>
<affiliation wicri:level="3">
<nlm:affiliation>Host-Pathogen translational research group, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Host-Pathogen translational research group, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Dubucquoi, Sylvain" sort="Dubucquoi, Sylvain" uniqKey="Dubucquoi S" first="Sylvain" last="Dubucquoi">Sylvain Dubucquoi</name>
<affiliation wicri:level="1">
<nlm:affiliation>Institut d'Immunologie, Centre Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille Cedex, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut d'Immunologie, Centre Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille Cedex</wicri:regionArea>
<wicri:noRegion>Lille Cedex</wicri:noRegion>
<wicri:noRegion>Lille Cedex</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Dessein, Rodrigue" sort="Dessein, Rodrigue" uniqKey="Dessein R" first="Rodrigue" last="Dessein">Rodrigue Dessein</name>
<affiliation wicri:level="3">
<nlm:affiliation>Host-Pathogen translational research group, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Host-Pathogen translational research group, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Gosset, Philippe" sort="Gosset, Philippe" uniqKey="Gosset P" first="Philippe" last="Gosset">Philippe Gosset</name>
<affiliation wicri:level="3">
<nlm:affiliation>Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8204, Lille, France; Institut National de la Santé et de la Recherche Médicale, U1019, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8204, Lille, France; Institut National de la Santé et de la Recherche Médicale, U1019, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Mathieu, Daniel" sort="Mathieu, Daniel" uniqKey="Mathieu D" first="Daniel" last="Mathieu">Daniel Mathieu</name>
<affiliation wicri:level="3">
<nlm:affiliation>Pôle de Réanimation, Hôpital Roger Salengro, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Pôle de Réanimation, Hôpital Roger Salengro, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Guery, Benoit" sort="Guery, Benoit" uniqKey="Guery B" first="Benoit" last="Guery">Benoit Guery</name>
<affiliation wicri:level="3">
<nlm:affiliation>Host-Pathogen translational research group, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Host-Pathogen translational research group, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24551142</idno>
<idno type="pmid">24551142</idno>
<idno type="doi">10.1371/journal.pone.0088716</idno>
<idno type="wicri:Area/PubMed/Corpus">001A50</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A50</idno>
<idno type="wicri:Area/PubMed/Curation">001A50</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A50</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001935</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001935</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?</title>
<author>
<name sortKey="Faure, Emmanuel" sort="Faure, Emmanuel" uniqKey="Faure E" first="Emmanuel" last="Faure">Emmanuel Faure</name>
<affiliation wicri:level="3">
<nlm:affiliation>Host-Pathogen translational research group, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Host-Pathogen translational research group, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Poissy, Julien" sort="Poissy, Julien" uniqKey="Poissy J" first="Julien" last="Poissy">Julien Poissy</name>
<affiliation wicri:level="3">
<nlm:affiliation>Pôle de Réanimation, Hôpital Roger Salengro, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Pôle de Réanimation, Hôpital Roger Salengro, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Goffard, Anne" sort="Goffard, Anne" uniqKey="Goffard A" first="Anne" last="Goffard">Anne Goffard</name>
<affiliation wicri:level="3">
<nlm:affiliation>Laboratoire de Virologie, Centre de Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Virologie, Centre de Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Fournier, Clement" sort="Fournier, Clement" uniqKey="Fournier C" first="Clement" last="Fournier">Clement Fournier</name>
<affiliation wicri:level="3">
<nlm:affiliation>Clinique des Maladies Respiratoires, Endoscopie bronchique et pleurale - Endoscopie Interventionnelle, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinique des Maladies Respiratoires, Endoscopie bronchique et pleurale - Endoscopie Interventionnelle, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kipnis, Eric" sort="Kipnis, Eric" uniqKey="Kipnis E" first="Eric" last="Kipnis">Eric Kipnis</name>
<affiliation wicri:level="3">
<nlm:affiliation>Host-Pathogen translational research group, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Host-Pathogen translational research group, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Titecat, Marie" sort="Titecat, Marie" uniqKey="Titecat M" first="Marie" last="Titecat">Marie Titecat</name>
<affiliation wicri:level="3">
<nlm:affiliation>Institut de Microbiologie, Centre Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Microbiologie, Centre Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Bortolotti, Perinne" sort="Bortolotti, Perinne" uniqKey="Bortolotti P" first="Perinne" last="Bortolotti">Perinne Bortolotti</name>
<affiliation wicri:level="3">
<nlm:affiliation>Host-Pathogen translational research group, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Host-Pathogen translational research group, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Martinez, Laura" sort="Martinez, Laura" uniqKey="Martinez L" first="Laura" last="Martinez">Laura Martinez</name>
<affiliation wicri:level="3">
<nlm:affiliation>Host-Pathogen translational research group, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Host-Pathogen translational research group, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Dubucquoi, Sylvain" sort="Dubucquoi, Sylvain" uniqKey="Dubucquoi S" first="Sylvain" last="Dubucquoi">Sylvain Dubucquoi</name>
<affiliation wicri:level="1">
<nlm:affiliation>Institut d'Immunologie, Centre Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille Cedex, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut d'Immunologie, Centre Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille Cedex</wicri:regionArea>
<wicri:noRegion>Lille Cedex</wicri:noRegion>
<wicri:noRegion>Lille Cedex</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Dessein, Rodrigue" sort="Dessein, Rodrigue" uniqKey="Dessein R" first="Rodrigue" last="Dessein">Rodrigue Dessein</name>
<affiliation wicri:level="3">
<nlm:affiliation>Host-Pathogen translational research group, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Host-Pathogen translational research group, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Gosset, Philippe" sort="Gosset, Philippe" uniqKey="Gosset P" first="Philippe" last="Gosset">Philippe Gosset</name>
<affiliation wicri:level="3">
<nlm:affiliation>Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8204, Lille, France; Institut National de la Santé et de la Recherche Médicale, U1019, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8204, Lille, France; Institut National de la Santé et de la Recherche Médicale, U1019, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Mathieu, Daniel" sort="Mathieu, Daniel" uniqKey="Mathieu D" first="Daniel" last="Mathieu">Daniel Mathieu</name>
<affiliation wicri:level="3">
<nlm:affiliation>Pôle de Réanimation, Hôpital Roger Salengro, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Pôle de Réanimation, Hôpital Roger Salengro, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Guery, Benoit" sort="Guery, Benoit" uniqKey="Guery B" first="Benoit" last="Guery">Benoit Guery</name>
<affiliation wicri:level="3">
<nlm:affiliation>Host-Pathogen translational research group, Université de Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Host-Pathogen translational research group, Université de Lille 2, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j">PloS one</title>
<idno type="eISSN">1932-6203</idno>
<imprint>
<date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adaptive Immunity (immunology)</term>
<term>Chemokine CXCL10 (metabolism)</term>
<term>Coronavirus (immunology)</term>
<term>Coronavirus Infections (immunology)</term>
<term>Coronavirus Infections (virology)</term>
<term>Fatal Outcome</term>
<term>Humans</term>
<term>Immunity, Innate (immunology)</term>
<term>Interferon-alpha (metabolism)</term>
<term>Interferon-gamma (metabolism)</term>
<term>Interleukin-10 (metabolism)</term>
<term>Interleukin-12 (metabolism)</term>
<term>Interleukin-17 (metabolism)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Middle East</term>
<term>Models, Immunological</term>
<term>Respiratory Tract Infections (immunology)</term>
<term>Respiratory Tract Infections (virology)</term>
<term>Translational Medical Research</term>
<term>Treatment Outcome</term>
<term>Virus Replication (physiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adulte d'âge moyen</term>
<term>Chimiokine CXCL10 (métabolisme)</term>
<term>Coronavirus (immunologie)</term>
<term>Humains</term>
<term>Immunité acquise (immunologie)</term>
<term>Immunité innée (immunologie)</term>
<term>Infections de l'appareil respiratoire (immunologie)</term>
<term>Infections de l'appareil respiratoire (virologie)</term>
<term>Infections à coronavirus (immunologie)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Interféron alpha (métabolisme)</term>
<term>Interféron gamma (métabolisme)</term>
<term>Interleukine-10 (métabolisme)</term>
<term>Interleukine-12 (métabolisme)</term>
<term>Interleukine-17 (métabolisme)</term>
<term>Issue fatale</term>
<term>Modèles immunologiques</term>
<term>Moyen Orient</term>
<term>Mâle</term>
<term>Recherche médicale translationnelle</term>
<term>Réplication virale (physiologie)</term>
<term>Résultat thérapeutique</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Chemokine CXCL10</term>
<term>Interferon-alpha</term>
<term>Interferon-gamma</term>
<term>Interleukin-10</term>
<term>Interleukin-12</term>
<term>Interleukin-17</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Coronavirus</term>
<term>Immunité acquise</term>
<term>Immunité innée</term>
<term>Infections de l'appareil respiratoire</term>
<term>Infections à coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>Adaptive Immunity</term>
<term>Coronavirus</term>
<term>Coronavirus Infections</term>
<term>Immunity, Innate</term>
<term>Respiratory Tract Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Chimiokine CXCL10</term>
<term>Interféron alpha</term>
<term>Interféron gamma</term>
<term>Interleukine-10</term>
<term>Interleukine-12</term>
<term>Interleukine-17</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr">
<term>Réplication virale</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr">
<term>Infections de l'appareil respiratoire</term>
<term>Infections à coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en">
<term>Coronavirus Infections</term>
<term>Respiratory Tract Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Fatal Outcome</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Middle East</term>
<term>Models, Immunological</term>
<term>Translational Medical Research</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adulte d'âge moyen</term>
<term>Humains</term>
<term>Issue fatale</term>
<term>Modèles immunologiques</term>
<term>Moyen Orient</term>
<term>Mâle</term>
<term>Recherche médicale translationnelle</term>
<term>Résultat thérapeutique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">One year after the occurrence of the first case of infection by the Middle East Respiratory Syndrome coronavirus (MERS-CoV) there is no clear consensus on the best treatment to propose. The World Health Organization, as well as several other national agencies, are still working on different clinical approaches to implement the most relevant treatment in MERS-CoV infection. We compared innate and adaptive immune responses of two patients infected with MERS-CoV to understand the underlying mechanisms involved in the response and propose potential therapeutic approaches. Broncho-alveolar lavage (BAL) of the first week and sera of the first month from the two patients were used in this study. Quantitative polymerase chain reaction (qRTPCR) was performed after extraction of RNA from BAL cells of MERS-CoV infected patients and control patients. BAL supernatants and sera were used to assess cytokines and chemokines secretion by enzyme-linked immunosorbent assay. The first patient died rapidly after 3 weeks in the intensive care unit, the second patient still recovers from infection. The patient with a poor outcome (patient 1), compared to patient 2, did not promote type-1 Interferon (IFN), and particularly IFNα, in response to double stranded RNA (dsRNA) from MERS-CoV. The absence of IFNα, known to promote antigen presentation in response to viruses, impairs the development of a robust antiviral adaptive Th-1 immune response. This response is mediated by IL-12 and IFNγ that decreases viral clearance; levels of both of these mediators were decreased in patient 1. Finally, we confirm previous in vitro findings that MERS-CoV can drive IL-17 production in humans. Host recognition of viral dsRNA determines outcome in the early stage of MERS-CoV infection. We highlight the critical role of IFNα in this initial stage to orchestrate a robust immune response and bring substantial arguments for the indication of early IFNα treatment during MERS-CoV infection. </div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">24551142</PMID>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection">
<Journal>
<ISSN IssnType="Electronic">1932-6203</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>9</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>PloS one</Title>
<ISOAbbreviation>PLoS ONE</ISOAbbreviation>
</Journal>
<ArticleTitle>Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?</ArticleTitle>
<Pagination>
<MedlinePgn>e88716</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0088716</ELocationID>
<Abstract>
<AbstractText>One year after the occurrence of the first case of infection by the Middle East Respiratory Syndrome coronavirus (MERS-CoV) there is no clear consensus on the best treatment to propose. The World Health Organization, as well as several other national agencies, are still working on different clinical approaches to implement the most relevant treatment in MERS-CoV infection. We compared innate and adaptive immune responses of two patients infected with MERS-CoV to understand the underlying mechanisms involved in the response and propose potential therapeutic approaches. Broncho-alveolar lavage (BAL) of the first week and sera of the first month from the two patients were used in this study. Quantitative polymerase chain reaction (qRTPCR) was performed after extraction of RNA from BAL cells of MERS-CoV infected patients and control patients. BAL supernatants and sera were used to assess cytokines and chemokines secretion by enzyme-linked immunosorbent assay. The first patient died rapidly after 3 weeks in the intensive care unit, the second patient still recovers from infection. The patient with a poor outcome (patient 1), compared to patient 2, did not promote type-1 Interferon (IFN), and particularly IFNα, in response to double stranded RNA (dsRNA) from MERS-CoV. The absence of IFNα, known to promote antigen presentation in response to viruses, impairs the development of a robust antiviral adaptive Th-1 immune response. This response is mediated by IL-12 and IFNγ that decreases viral clearance; levels of both of these mediators were decreased in patient 1. Finally, we confirm previous in vitro findings that MERS-CoV can drive IL-17 production in humans. Host recognition of viral dsRNA determines outcome in the early stage of MERS-CoV infection. We highlight the critical role of IFNα in this initial stage to orchestrate a robust immune response and bring substantial arguments for the indication of early IFNα treatment during MERS-CoV infection. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Faure</LastName>
<ForeName>Emmanuel</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Host-Pathogen translational research group, Université de Lille 2, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Poissy</LastName>
<ForeName>Julien</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Pôle de Réanimation, Hôpital Roger Salengro, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Goffard</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Laboratoire de Virologie, Centre de Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fournier</LastName>
<ForeName>Clement</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Clinique des Maladies Respiratoires, Endoscopie bronchique et pleurale - Endoscopie Interventionnelle, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kipnis</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Host-Pathogen translational research group, Université de Lille 2, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Titecat</LastName>
<ForeName>Marie</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Institut de Microbiologie, Centre Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bortolotti</LastName>
<ForeName>Perinne</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Host-Pathogen translational research group, Université de Lille 2, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Martinez</LastName>
<ForeName>Laura</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Host-Pathogen translational research group, Université de Lille 2, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dubucquoi</LastName>
<ForeName>Sylvain</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Institut d'Immunologie, Centre Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille Cedex, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dessein</LastName>
<ForeName>Rodrigue</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Host-Pathogen translational research group, Université de Lille 2, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gosset</LastName>
<ForeName>Philippe</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8204, Lille, France; Institut National de la Santé et de la Recherche Médicale, U1019, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mathieu</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Pôle de Réanimation, Hôpital Roger Salengro, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Guery</LastName>
<ForeName>Benoit</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Host-Pathogen translational research group, Université de Lille 2, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>02</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>PLoS One</MedlineTA>
<NlmUniqueID>101285081</NlmUniqueID>
<ISSNLinking>1932-6203</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C114753">CXCL10 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054357">Chemokine CXCL10</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>130068-27-8</RegistryNumber>
<NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>187348-17-0</RegistryNumber>
<NameOfSubstance UI="D018664">Interleukin-12</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>82115-62-6</RegistryNumber>
<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D056704" MajorTopicYN="N">Adaptive Immunity</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D054357" MajorTopicYN="N">Chemokine CXCL10</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017934" MajorTopicYN="N">Coronavirus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018664" MajorTopicYN="N">Interleukin-12</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D020381" MajorTopicYN="N">Interleukin-17</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008877" MajorTopicYN="N">Middle East</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018448" MajorTopicYN="N">Models, Immunological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012141" MajorTopicYN="N">Respiratory Tract Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D057170" MajorTopicYN="Y">Translational Medical Research</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2013</Year>
<Month>10</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2014</Year>
<Month>01</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2014</Year>
<Month>2</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2014</Year>
<Month>2</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2014</Year>
<Month>10</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">24551142</ArticleId>
<ArticleId IdType="doi">10.1371/journal.pone.0088716</ArticleId>
<ArticleId IdType="pii">PONE-D-13-41402</ArticleId>
<ArticleId IdType="pmc">PMC3925152</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Nat Rev Mol Cell Biol. 2001 May;2(5):378-86</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11331912</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Paediatr Respir Rev. 2008 Dec;9(4):243-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19026365</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Immunol. 2004 Jul;5(7):730-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15208624</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMC Immunol. 2005;6:2</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15655079</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Mol Immunol. 2004 Jun;1(3):193-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16219167</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2007 Aug;81(16):8692-706</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17537853</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Microbiol. 2009 Jun;7(6):439-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19430490</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cytokine Growth Factor Rev. 2010 Oct;21(5):315-24</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21112807</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Virology. 2011 Sep 15;418(1):40-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21810534</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Immunol. 2012 Mar;12(3):215-25</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22362354</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23075143</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Virology. 2013 Jan 5;435(1):37-45</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23217614</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>MBio. 2013;4(3):e00165-13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23631916</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Opin Immunol. 2013 Jun;25(3):373-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23669353</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2013 Jun 29;381(9885):2265-72</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23727167</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS Pathog. 2013;9(6):e1003410</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23825942</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Gen Virol. 2013 Aug;94(Pt 8):1749-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23620378</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):E3189-97</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23918362</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Infect Dis. 2013 Sep;13(9):752-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23891402</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Infect Dis. 2013 Oct;17(10):e792-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23993766</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Opin Immunol. 2008 Feb;20(1):17-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18272355</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Virus Res. 2008 Apr;133(1):101-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17451827</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Immunol. 2002 Sep;2(9):675-87</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12209136</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>France</li>
</country>
<region>
<li>Hauts-de-France</li>
<li>Nord-Pas-de-Calais</li>
</region>
<settlement>
<li>Lille</li>
</settlement>
</list>
<tree>
<country name="France">
<region name="Hauts-de-France">
<name sortKey="Faure, Emmanuel" sort="Faure, Emmanuel" uniqKey="Faure E" first="Emmanuel" last="Faure">Emmanuel Faure</name>
</region>
<name sortKey="Bortolotti, Perinne" sort="Bortolotti, Perinne" uniqKey="Bortolotti P" first="Perinne" last="Bortolotti">Perinne Bortolotti</name>
<name sortKey="Dessein, Rodrigue" sort="Dessein, Rodrigue" uniqKey="Dessein R" first="Rodrigue" last="Dessein">Rodrigue Dessein</name>
<name sortKey="Dubucquoi, Sylvain" sort="Dubucquoi, Sylvain" uniqKey="Dubucquoi S" first="Sylvain" last="Dubucquoi">Sylvain Dubucquoi</name>
<name sortKey="Fournier, Clement" sort="Fournier, Clement" uniqKey="Fournier C" first="Clement" last="Fournier">Clement Fournier</name>
<name sortKey="Goffard, Anne" sort="Goffard, Anne" uniqKey="Goffard A" first="Anne" last="Goffard">Anne Goffard</name>
<name sortKey="Gosset, Philippe" sort="Gosset, Philippe" uniqKey="Gosset P" first="Philippe" last="Gosset">Philippe Gosset</name>
<name sortKey="Guery, Benoit" sort="Guery, Benoit" uniqKey="Guery B" first="Benoit" last="Guery">Benoit Guery</name>
<name sortKey="Kipnis, Eric" sort="Kipnis, Eric" uniqKey="Kipnis E" first="Eric" last="Kipnis">Eric Kipnis</name>
<name sortKey="Martinez, Laura" sort="Martinez, Laura" uniqKey="Martinez L" first="Laura" last="Martinez">Laura Martinez</name>
<name sortKey="Mathieu, Daniel" sort="Mathieu, Daniel" uniqKey="Mathieu D" first="Daniel" last="Mathieu">Daniel Mathieu</name>
<name sortKey="Poissy, Julien" sort="Poissy, Julien" uniqKey="Poissy J" first="Julien" last="Poissy">Julien Poissy</name>
<name sortKey="Titecat, Marie" sort="Titecat, Marie" uniqKey="Titecat M" first="Marie" last="Titecat">Marie Titecat</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001935 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001935 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:24551142
   |texte=   Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:24551142" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021